Jamie B. Miyamoto
- Oncology top 2%
- HER2/EGFR in Cancer Research 20
- CAR-T cell therapy research 4
- Peptidase Inhibition and Analysis 4
-
- Monoclonal and Polyclonal Antibodies Research 20
- Immunology and Allergy top 10%
- Cell Adhesion Molecules Research 4
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 5
- Genetics top 10%
-
- Glycosylation and Glycoproteins Research 5
-
- Multiple Myeloma Research and Treatments 4
Jamie B. Miyamoto
30 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 64
- Oncology 1.0k
- Radiology, Nuclear Medicine and Imaging 855
- Immunology and Allergy 62
- Pathology and Forensic Medicine 156
- Genetics 90
Countries citing papers authored by Jamie B. Miyamoto
This map shows the geographic impact of Jamie B. Miyamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie B. Miyamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie B. Miyamoto more than expected).
Fields of papers citing papers by Jamie B. Miyamoto
This network shows the impact of papers produced by Jamie B. Miyamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie B. Miyamoto. The network helps show where Jamie B. Miyamoto may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jamie B. Miyamoto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 19 | |
| 2 | 2016 | 231 | |
| 3 | 2016 | 110 | |
| 4 | 2016 | 8 | |
| 5 | 2016 | 56 | |
| 6 | 2015 | 4 | |
| 7 | 2014 | 104 | |
| 8 | 2014 | 4 | |
| 9 | 2014 | 9 | |
| 10 | 2014 | 4 | |
| 11 | 2012 | 1 | |
| 12 | 2010 | 291 | |
| 13 | 2010 | 1 | |
| 14 | 2009 | 20 | |
| 15 | 2009 | 32 | |
| 16 | 2008 | 60 | |
| 17 | 2008 | 2 | |
| 18 | Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies | 2007 | 2 |
| 19 | The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms | 2007 | 1 |
| 20 | 2007 | 41 |
About Jamie B. Miyamoto
Jamie B. Miyamoto is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy, having authored 31 papers that have together received 1.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (20 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Glycosylation and Glycoproteins Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), CAR-T cell therapy research (4 papers), Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (4 papers) and Cell Adhesion Molecules Research (4 papers). The work is most often cited by research in Oncology (1.0k citations), Radiology, Nuclear Medicine and Imaging (855 citations) and Immunology and Allergy (62 citations). Jamie B. Miyamoto has collaborated with scholars based in United States. Frequent co-authors include Peter D. Senter, Xinqun Zhang, Dennis R. Benjamin, Nicole M. Okeley, Martha E. Anderson, Kim K. Emmerton, Stephen C. Alley, Scott C. Jeffrey, Robert P. Lyon and Eric L. Sievers. Their work appears in journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.